The Future of Nonsteroidal Topical Therapy in Dermatology

In a discussion on the future of nonsteroidal topical therapy in dermatology, two experts present contrasting views on the role of topical steroids versus nonsteroidal options. Dr. Strober argues for the gradual phasing out of topical steroids due to their side effects, emphasizing the effectiveness and safety of nonsteroidal therapies like PD4 inhibitors, such as rifumolast and tapinov, which have shown significant improvement in conditions like psoriasis and atopic dermatitis. He highlights that these therapies are becoming more accessible and have pediatric indications, suggesting a shift towards steroid-sparing treatments. Conversely, Dr. Gordon defends the ongoing relevance of topical steroids, citing their effectiveness, safety, and convenience in treating various skin conditions. He stresses that despite the emergence of new treatments, topical steroids remain the first-line therapy for many dermatological issues, due to their quick onset and ease of use. Both speakers agree on the importance of developing new therapies but differ on whether nonsteroidals will replace topical steroids. Ultimately, the debate concludes with Dr. Gordon declaring topical steroids as ongoing champions of topical therapy, while Dr. Strober envisions a future where nonsteroidal options dominate.